These results show that when combined, these markers can help to predict progression of IBD to CRC through regular monitoring (once a year), where reducing expression of CA724 in an IBD patient combined with increasing expression of RUNX1 and TIMP1 may be an alarm to perform additional testing for CRC, whereas expression of CEA may help confirm onset of an early CRC phenotype. The gene discussed is CEACAM5; the disease is colorectal carcinoma.